The Experts below are selected from a list of 38043 Experts worldwide ranked by ideXlab platform
Timothy L Frankel - One of the best experts on this subject based on the ideXlab platform.
-
Immunotherapy for Pancreatic Ductal Adenocarcinoma.
Journal of surgical oncology, 2021Co-Authors: Eileen Carpenter, Sarah Nelson, Filip Bednar, Clifford Cho, Hari Nathan, Vaibhav Sahai, Marina Pasca Di Magliano, Timothy L FrankelAbstract:Pancreatic Ductal Adenocarcinoma (PDAC) remains a lethal cancer with an urgent need for better medical therapies. Efforts have been made to investigate the efficacy of immunotherapy, particularly given the hallmarks of immune suppression and exhaustion in PDAC tumors. Here, we review the molecular components responsible for the immune-privileged state in PDAC and provide an overview of the immunotherapeutic strategies for PDAC including vaccine therapy, checkpoint blockade, myeloid-targeted therapy, and immune agonist therapy.
Koji Yamaguchi - One of the best experts on this subject based on the ideXlab platform.
-
Prognostic Impact of Hyaluronan and Its Regulators in Pancreatic Ductal Adenocarcinoma
PLoS ONE, 2013Co-Authors: Xiao-bo Cheng, Shiro Kohi, Norihiro Sato, Koji YamaguchiAbstract:Background Although Pancreatic Ductal Adenocarcinoma is characterized by an abundant stroma enriched with hyaluronan (HA), the prognostic impact of HA and its regulators remains unknown.
-
Association of microRNA-21 expression with its targets, PDCD4 and TIMP3, in Pancreatic Ductal Adenocarcinoma
Modern Pathology, 2011Co-Authors: Yuichi Nagao, Masanori Hisaoka, Atsuji Matsuyama, Shuichi Kanemitsu, Tetsuo Hamada, Tokihiko Fukuyama, Ryuji Nakano, Akihiko Uchiyama, Masahiko Kawamoto, Koji YamaguchiAbstract:Since the discovery of small non-coding RNAs, the analyses of microRNA (miRNA) expression patterns in human cancer have provided new insights into cancer biology. miRNA-21 has been suggested to be one of the miRNAs that have an important role in the development or biological behavior of a variety of malignancies, including Pancreatic cancer. This study was conducted to evaluate the relationship between the expression of miRNA-21 and that of its molecular targets, programmed cell death 4 (PDCD4) and tissue inhibitor of metalloproteinase (TIMP3), in Pancreatic Ductal Adenocarcinoma. The study included 65 Pancreatic Ductal Adenocarcinomas and 5 normal Pancreatic tissue specimens for comparison. The miRNA expression profiling of five selected Pancreatic Ductal Adenocarcinomas and five normal Pancreatic specimens was performed using a microarray platform, and was evaluated by a hierarchical clustering analysis. The miRNA most highly expressed in Pancreatic Ductal Adenocarcinomas (ie, miRNA-21) was further assessed by quantitative real-time reverse transcription PCR (RT-PCR) assays in the 65 Pancreatic Ductal Adenocarcinoma cases. The expression pattern of its molecular targets (eg, PDCD4 and TIMP3) in Pancreatic Ductal Adenocarcinoma was examined immunohistochemically. In the microarray analyses, 28 miRNAs were upregulated in Pancreatic Ductal Adenocarcinoma compared with normal Pancreatic tissue, whereas 48 miRNAs were downregulated. miRNA-21 was the most significantly overexpressed miRNA in the Pancreatic Ductal Adenocarcinomas analyzed, and was also highly expressed in 75% of the 65 Pancreatic Ductal Adenocarcinomas examined by real-time RT-PCR. High miRNA-21 expression was correlated with a worse prognosis in the Pancreatic Ductal Adenocarcinoma patients (P=0.045). The immunohistochemical expression patterns of PDCD4 (reduced nuclear staining pattern) and TIMP3 (downregulated expression) were significantly associated with both the upregulated miR-21 expression (P
-
Efficacy of three-dimensional fast imaging with steady precession dynamic MR imaging in evaluating Pancreatic Ductal Adenocarcinoma
Clinical Imaging, 2001Co-Authors: Hiroyuki Irie, Hiroshi Honda, Hitoshi Aibe, Toshiro Kuroiwa, Kengo Yoshimitsu, Kenji Shinozaki, Koji Yamaguchi, Mitsuo Shimada, Kouji MasudaAbstract:To compare the diagnostic efficacy of three-dimensional fast imaging with steady precession (3D-FISP) dynamic MR imaging in assessing Pancreatic Ductal Adenocarcinoma with conventional MR imaging and helical CT, 15 patients with surgically proven Pancreatic Ductal Adenocarcinoma were studied. Contrast-to-noise ratio (CNR) of the tumor, tumor detectability, local tumor extension, and vascular involvement were evaluated for all techniques. The results indicate that 3D-FISP dynamic MR imaging may improve the imaging assessment of Pancreatic Ductal Adenocarcinoma.
Adam E Frampton - One of the best experts on this subject based on the ideXlab platform.
-
Usefulness of Measuring microRNAs in Bile and Plasma for Pancreatic Ductal Adenocarcinoma Diagnosis
American Journal of Gastroenterology, 2015Co-Authors: Tessa Y.s. Le Large, Adam E Frampton, Justin Stebbing, Laura L. Meijer, Geert Kazemier, Elisa GiovannettiAbstract:Usefulness of Measuring microRNAs in Bile and Plasma for Pancreatic Ductal Adenocarcinoma Diagnosis
-
microRNAs as markers of survival and chemoresistance in Pancreatic Ductal Adenocarcinoma.
Expert Review of Anticancer Therapy, 2011Co-Authors: Adam E Frampton, Jonathan Krell, Jimmy Jacob, Justin Stebbing, Long R. Jiao, Leandro CastellanoAbstract:Evaluation of: Preis M, Gardner TB, Gordon SR et al. microRNA-10b expression correlates with response to neoadjuvant therapy and survival in Pancreatic Ductal Adenocarcinoma. Clin. Cancer Res. 17(17), 5812–5821 (2011).microRNAs (miRs) are a recently recognized class of noncoding short RNAs, 17–25 nucleotides in length, that play a role in post-transcriptional gene regulation by translational repression and/or mRNA degradation. Various miRs have been highlighted in Pancreatic cancer development and metastasis, and as potential clinical diagnostic/prognostic biomarkers. Recently, studies have indicated that miRs are responsible for resistance to chemotherapeutic agents. The miR-10b has been identified as a ‘metastamiR’ in various tumor types, notably breast cancer, but data surrounding its relevance in Pancreatic Ductal Adenocarcinoma has been sparse. The evaluated article presents data indicating that miR-10b is upregulated in Pancreatic Ductal Adenocarcinoma and can be used as a diagnostic marker in endos...
Elisa Giovannetti - One of the best experts on this subject based on the ideXlab platform.
-
Usefulness of Measuring microRNAs in Bile and Plasma for Pancreatic Ductal Adenocarcinoma Diagnosis
American Journal of Gastroenterology, 2015Co-Authors: Tessa Y.s. Le Large, Adam E Frampton, Justin Stebbing, Laura L. Meijer, Geert Kazemier, Elisa GiovannettiAbstract:Usefulness of Measuring microRNAs in Bile and Plasma for Pancreatic Ductal Adenocarcinoma Diagnosis
Takao Ohtsuka - One of the best experts on this subject based on the ideXlab platform.
-
Surveillance of patients with intraDuctal papillary mucinous neoplasm with and without pancreatectomy with special reference to the incidence of concomitant Pancreatic Ductal Adenocarcinoma.
Surgery, 2018Co-Authors: Kenjiro Date, Takao Ohtsuka, So Nakamura, Naoki Mochidome, Yasuhisa Mori, Yoshihiro Miyasaka, Yoshinao Oda, Masafumi NakamuraAbstract:Abstract Background The presence of an intraDuctal papillary mucinous neoplasm is important in the detection of concomitant Pancreatic Ductal Adenocarcinoma. The aim of this study was to elucidate the incidence and timing of development of concomitant Pancreatic Ductal Adenocarcinoma in patients with and without pancreatectomy for intraDuctal papillary mucinous neoplasm. Methods We reviewed retrospectively the surveillance data for 22 patients who underwent pancreatectomy for Pancreatic Ductal Adenocarcinoma concomitant with intraDuctal papillary mucinous neoplasm (Pancreatic Ductal Adenocarcinoma-resection group), 180 who underwent pancreatectomy for intraDuctal papillary mucinous neoplasm (intraDuctal papillary mucinous neoplasm-resection group), and 263 whose intraDuctal papillary mucinous neoplasms were left untreated (nonresection group). The incidence and timing of the development of a concomitant Pancreatic Ductal Adenocarcinoma during the surveillance of patients with and without partial pancreatectomy for intraDuctal papillary mucinous neoplasm were investigated using the Kaplan-Meier method. Results During a median surveillance period of 40 months (range 6–262 months), 5 patients in the Pancreatic Ductal Adenocarcinoma-resection group, 6 in the intraDuctal papillary mucinous neoplasm-resection group, and 8 in the nonresection group developed concomitant Pancreatic Ductal Adenocarcinoma. The estimated 5-year (17%) and 10-year (56%) cumulative incidences of secondary Pancreatic Ductal Adenocarcinoma in the Pancreatic Ductal Adenocarcinoma-resection group were significantly greater than those in the other two groups (P Conclusion Long-term (≥5-year) surveillance in patients with intraDuctal papillary mucinous neoplasm is necessary and important because of the potential for development of concomitant Pancreatic Ductal Adenocarcinoma. Those with a history of resection of concomitant Pancreatic Ductal Adenocarcinoma at the time of the initial operation are at quite high risk for the development of secondary Pancreatic Ductal Adenocarcinoma.
-
Claudin-4 expression predicts survival in Pancreatic Ductal Adenocarcinoma.
Annals of Surgical Oncology, 2011Co-Authors: Kosuke Tsutsumi, Takao Ohtsuka, Kenoki Ohuchida, Kazuhiro Mizumoto, Norihiro Sato, Reiko Tanabe, Katsuya Morimatsu, Tadashi Kayashima, Hayato Fujita, Shunichi TakahataAbstract:Background Identification of prognostic markers would be useful in the clinical management of patients with Pancreatic Ductal Adenocarcinoma (PDAC). The clinical relevance of claudin-4 (CLDN4), recently identified as overexpressed in PDAC, is unknown.
-
MicroRNA Expression Analyses in Preoperative Pancreatic Juice Samples of Pancreatic Ductal Adenocarcinoma
JOP : Journal of the pancreas, 2010Co-Authors: Yoshihiko Sadakari, Takao Ohtsuka, Kenoki Ohuchida, Kosuke Tsutsumi, Shunichi Takahata, Masafumi Nakamura, Kazuhiro Mizumoto, Masao TanakaAbstract:Context Cytological assessment of Pancreatic juice is commonly used to diagnose Pancreatic Ductal Adenocarcinoma; however, the sensitivity of cytological assessment has been reported to be low. MicroRNAs are small RNAs regulating various cellular processes and have recently been identified as possible markers of malignant diseases including Pancreatic Ductal Adenocarcinoma. Objective The purposes of this study were to prove the existence of microRNAs in Pancreatic juice and to determine whether specific microRNAs in Pancreatic juice could be used for detecting Pancreatic Ductal Adenocarcinoma. Methods Relative expression levels of microRNA-21 and microRNA-155 in formalin-fixed paraffin-embedded tissues of resected specimens (no. 13) and Pancreatic juice samples collected using preoperative endoscopic retrograde cholangiopancreatography (no. 21) were quantified and their expression levels were then compared to Pancreatic Ductal Adenocarcinoma and chronic pancreatitis. Results Relative expression levels of microRNA-21 in tissue and Pancreatic juice samples were significantly higher in Pancreatic Ductal Adenocarcinoma than those in chronic pancreatitis (P=0.009 and P=0.021, respectively). The same results were obtained in the expression levels of microRNA-155 in tissue and Pancreatic juice between Pancreatic Ductal Adenocarcinoma and chronic pancreatitis (P=0.014 and P=0.021, respectively). Expression levels of microRNA-21 and microRNA-155 did not correlate with the preoperative cytological results of Pancreatic juice. Conclusion MicroRNA-21 and microRNA-155 in Pancreatic juice have the potential of becoming biomarkers for diagnosing Pancreatic Ductal Adenocarcinoma. Image: Non-atypical cells in Pancreatic juice.
